Prognostic importance of Mean Platelet Volume/ Platelet Ratio Before Treatment in Patients with Metastatic Pancreatic Cancer

Yıl 2023, , 51 - 59, 19.03.2023

Onur Yazdan Balçık Yusuf İlhan Bilgin Demir

https://doi.org/10.5798/dicletip.1266716

Öz

Objectives: Pancreatic cancer (PC) is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume/ platelet (MPV/PLT) and platelet indices such as MPV and plateletcrit (PCT) have a prognostic significance in patients with metastatic PC.
Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patient’s demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival (OS) and progression-free survival (PFS) were also recorded. There were 80 patients in our study.
Results: Median PFS was found 6.2 months for MPV/PLT ratio <0.045 group and 6.3 months for MPV/PLT ratio >0.045 group retrospectively. The median PFS of the MPV/PLT ratio ≤0.045 groupwas shorter than MPV/PLT ratio >0.045 group, but there wasn’t statistically meaningful difference between the groups (p:0,957). Median OS for the MPV/PLT ratio ≤0.045 groupwas 10.1 months and the MPV/PLT ratio for the >0.045 group was 9 months, but there wasn’t statistically significant difference between the groups (p:0.506).There was nosurvival difference between the groups when comparing both MPV and PCT status.
Conclusion: MPV/PLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

Anahtar Kelimeler

Metatatik pancreatic cancer, Mean platelet volume (MPV), Progression-free survival(PFS)

Kaynakça

• 1. Bray F., Ferlay J., Soerjomataram I., et all. Global cancer statistics, a cancer journal for clinicians, 2018; 68(6): 394-424.
• 2. Chen W., Zheng R., Baade P.D., et all. Cancer statistics in China, a cancer journal for clinicians, 2015; 66(2): 115-32.
• 3. Tinchon C., Hubmann E., Pichler A., et all. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma,Actaoncologica, 2017; 52(6): 1231-3.
• 4. Torre L.A., Bray F., Siegel R.L., et all. Global cancer statistics, a cancer journal for clinicians, 2015; 65(2): 87-108.